The prognosis of childhood malignancies has improved dramatically in the past 20 years. Acute lymphoblastic leukaemia now has at least a 60% five year disease free survival,' but curative chemotherapy and radiotherapy cause major immunosuppression.2 Infection was the cause of death in 8-3% of one cohort of children with acute lymphoblastic leukaemia,3 and measles accounted for between 20 and 40% of these deaths. In a more recent study 15 of 51 deaths (29%) among children with acute lymphoblastic leukaemia in clinical remission were attributed to measles. 4 Encephalomyelitis occurs in one per thousand normal children who develop measles, and between five and 10 children per million contracting measles will develop subacute sclerosing panencephalitis. 5 In immunosuppressed children the risk of developing encephalitis after measles is much greater. Kernaghan Increased vaccine uptake in the UK to provide herd immunity would greatly reduce the risk of contact with measles and therefore of its serious complications in immunosuppressed children.2 After the recent introduction of measles-mumpsrubella vaccine in the second year of life, the average measles vaccine coverage is now 91%22 and measles encephalitis should become much rarer in the future. Prior measles vaccination does not protect an immunosuppressed child against measles encephalitis.46 Indeed the occurrence of measles encephalitis in immunocompromised adults9 raises the possibility that even pre-existing natural immunity may not be completely protective. Certainly, prophylactic normal human immunoglobulin after measles contact is at best only partly effective.46 Unfortunately, a trial of hyperimmune measles immunoglobulin after exposure has proved inconclusive.6
In conclusion, diagnosis of measles encephalitis during life in immunosuppressed patients by detection ofviral antigen in brain biopsy material early in the illness may be precluded by the difficulty of localising disease within the brain. Alternatively the diagnosis could be made in some patients using a sensitive immunoassay to document a raised CSF:serum ratio of specific antibodies, ideally with confirmation of intrathecal antimeasles antibody synthesis by demonstrating a raised specific IgG ratio or confirmation of intrathecal immunoglobulin synthesis with a raised IgG index. In future cases, assay of measles virus RNA in CSF by reverse transcription and the polymerase chain reaction23 might be attempted. Detection of herpes simplex virus DNA in CSF has already proved a valuable diagnostic test for herpes simplex encephalitis.24 Early empirical treatment with tribavirin might be beneficial, but prevention by increasing vaccine uptake and hence herd immunity in the general population could be more realistic goal. This paper was presented to the British Paediatric Neurology Association Meeting in Durham in January 1991. We are grateful to Dr P Morris Jones and Dr R F Stevens for their helpful comments.
